Table 5.

Costs and savings of colorectal cancer screening by screening strategy and scenario, 3% discounted to age 50 years^*

		Costs, $			Compared with no screening, $
Strategy	Scenario	Screening	Follow-up and surveillance†	Treatment of colorectal cancer	Savings‡	Total net costs§
No screening	Past	0	0	1927	—	—
	Present	0	0	2542	—	—
	Near future	0	0	3519	—	—
Hemoccult II	Past	71	788	1367	560	299
	Present	71	788	1707	835	23
	Near future	71	788	2121	1398	−539
Immunochemical FOBT	Past	325	1241	1172	755	810
	Present	325	1241	1451	1091	474
	Near future	325	1241	1762	1756	−191
Flexible sigmoidoscopy	Past	657	918	1111	816	759
	Present	657	918	1407	1135	440
	Near future	657	918	1813	1706	−131
Colonoscopy	Past	1397	858	990	937	1317
	Present	1397	858	1239	1304	951
	Near future	1397	858	1561	1958	296
Flexible sigmoidoscopy + Hemoccult II	Past	672	1206	1034	893	984
	Present	672	1206	1285	1257	621
	Near future	672	1206	1588	1931	−53

^*Costs and savings are expressed as the lifetime average per individual in the population. — = not applicable; FOBT = fecal occult blood test.

^†Includes costs of diagnostic follow-up, surveillance tests, and treatment of complications.

^‡Treatment costs without screening minus treatment costs for specific strategy.

^§Sum of costs for specific strategy minus sum of costs without screening.